NCT06355908View on ClinicalTrials.gov

IL13Rα2 CAR-T for Patients With r/r Glioma

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 21, 2024

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2027

Conditions
Glioma
Interventions
BIOLOGICAL

IL13Rα2 CAR-T

The IL13Rα2 CAR-T cells will be administered via intraventricular infusion every 2 weekly via an Ommaya reservoir.

Trial Locations (1)

Unknown

RECRUITING

Beijing Tiantan Hospital, Beijing

All Listed Sponsors
collaborator

TCRCure Biopharma Ltd.

INDUSTRY

lead

Yang Zhang

OTHER